Supplementary Material for: Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease – Future Promise, Present Fears

2017-09-28T13:27:21Z (GMT) by Mao Z. Ong A.C.M.
<p>The peroxisome proliferator-activated receptor superfamily (PPARs) comprises a class of nuclear receptors with significant effects in regulating multiple cellular pathways. Much research and clinical interest has surrounded the PPAR-γ isoform because of its key role in the transcriptional regulation of metabolic pathways and the efficacy of thiazolidinediones, the most clinically used PPAR-γ agonist, in the management of type 2 diabetes mellitus. In this review, we discuss the pathogenic role of PPAR-γ in experimental models of kidney disease, clinical trials of thiazolidinediones in diabetic and non-diabetic kidney disease, recent safety concerns surrounding PPAR-γ agonists and reflect on their potential use in ‘orphan’ kidney diseases.</p>